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Introduction
Patients with haematological malignancies admitted to
ICU have a high mortality rate. Identifying predictors of
mortality and survival may be useful for clinical decision
making and can help to improve survival. The differ-
ences in mortality rate and other outcomes between
recipients of HSCT and non-transplant haematologic
patients admitted to the ICU have been poorly studied.
Objectives
To compare survival rate after intensive care admission
between recipients of HSCT and non-transplant patients
with haematologic malignancies.
Patients and Methods
Prospective observational study of all consecutive
patients with haematologic malignancies admitted to the
ICU. Patients had been undergone to an HSCT or not.
Period: December 2012 through April 2014. Variables
that were analyzed included: demographics haematologi-
cal disease, stage of the haematological disease, main
reason for admission to the ICU, severity of illness
(APACHE II y SOFA), organ failure, need of organ sup-
port therapy, death rate in the Unit, in hospital and in
the following 28 days after admission. The Chi square
test was used to analyse categorical variables and the U
Mann -Whitney test to compare quantitative variables.
Results
63 consecutive patients were included and their data
analyzed. Twenty-seven (42.9%) have undergone an
HSCT and 36 did not. Acute leukemias were the main
hematological diagnosis that determined the transplant
(11 patients, 40.7%) and 51.9% of transplanted patients
were admitted in ICU in complete remission. HSCT
recipients tended to be younger [median age 51 (34-55)
vs. 57 (43-66); p = 0.01] and they were admitted to the
ICU in a worst clinical condition SOFA [10 (8-14) vs.
8 (4-11); p = 0.01] and APACHE II [26 (19-29) vs. 21
(16-28); p = 0.32]. The most frequent cause of admis-
sion to the ICU was respiratory failure (77.8 %), without
differences between both groups (p = 0.54). However,
recipients of HSCT needed more frequently invasive
mechanical ventilation (85.2% vs. 52.8%, p = 0.007) and
suffered significantly more liver failure (77.8% vs. 30.6%;
p < 0.001) and renal failure (85.2% vs. 44.4%, p < 0.001).
Haemodynamic failure was also more frequent in the
HSCT recipients (88.9% vs. 63.9%; p = 0.02). Hospital
mortality rate 28 days after ICU admission of patients with
HSCT was higher than for non-HSCT patients (92.6% vs.
44.4%; p < 0.001). There were no significant differences
between both groups in the rest of the analyzed variables.
Conclusions
Recipients of an HSCT have a significantly higher mortal-
ity rate and worse survival than non-transplant haematolo-
gic patients after intensive care admission. The causes for
such poor outcome could be the worst clinical condition
at admission, more need for invasive mechanical ventila-
tion and higher rate of organ failure in HSCT recipients.
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Knowing the reasons for these differences merit further
investigation and may help to improve survival of both
patients settings.
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